Antibiotic Dosing in Patients on Intermittent Hemodialysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-09-15

Study Completion Date

2022-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The adequacy of the currently used dosing regimen of glycopeptides (vancomycin and teicoplanin) and beta-lactam antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam, ceftazidim) in patients with end-stage kidney disease receiving intermittent hemodialysis is studied by evaluating pharmacokinetics-pharmacodynamics (PK-PD) target attainment. A population pharmacokinetic study is performed to assist the selection of the optimal individualized dose for patients undergoing intermittent dialysis, taking into consideration as many relevant variables as possible.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Serum Ceftazidime Concentrations in Hemodialysis Patients

NCT03634904

Bacterial Infections Ceftazidime Renal Failure Chronic Requiring Hemodialysis

UNKNOWN NA

Concentration of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid in the Blood During Renal Replacement Therapy in Longterm Renal Replacement Therapy Patients

NCT02007603

Infection During Hemodialysis

COMPLETED PHASE3

Clearance and Pharmacokinetics of Antibiotics in Renal Replacement Therapy

NCT03714789

Kidney Failure

COMPLETED

Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins

NCT04714853

Kidney Failure

UNKNOWN

Antimicrobial Use and Stewardship in an Outpatient Hemodialysis Unit

NCT03172039

End Stage Renal Failure on Dialysis Infection, Bacterial

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Failure, Chronic Antibiotics Hemodialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hemodialysis patients on amoxicillin-clavulanic acid

The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.

All blood and urine samples are analyzed for amoxicillin-clavulanic acid.